Related Experiment Video
Updated: Dec 3, 2025

10:00
Assessment of Selective mRNA Translation in Mammalian Cells by Polysome Profiling
Published on: October 28, 2014
28.7K
The Use of B-Cell Polysome Profiling to Validate Novel RPL5 (uL18) and RPL26 (uL24) Variants in Diamond-Blackfan
Alexander Ludlow1, Nicholas George1, Megan Glassford2
1Center for Immunobiology, Department of Biomedical Sciences, Western Michigan University Homer Stryker M.D. School of Medicine.
Journal of Pediatric Hematology/Oncology
|October 30, 2020
Summary
Diamond-Blackfan anemia (DBA) is a rare genetic disorder. Optimized polysome profiling in B-cells can functionally validate ribosomal protein variants of unknown significance in DBA patients.
Area of Science:
- Genetics
- Molecular Biology
- Hematology
Background:
- Diamond-Blackfan anemia (DBA) is a rare bone marrow failure syndrome often caused by mutations in ribosomal protein genes.
- Current genetic testing for DBA frequently identifies variants of unknown significance, hindering diagnosis and treatment.
- Functional validation of these variants is crucial for understanding disease mechanisms.
Observation:
- This study optimized polysome profiling in primary B-cells to assess ribosomal subunit function.
- The optimized method was applied to two children with DBA and novel missense variants in RPL5 and RPL26.
- Both patients exhibited reduced 60S and 80S ribosomal fractions compared to an unaffected parent.
Findings:
- Polysome profiling effectively identified a large ribosomal subunit defect in DBA patients with novel variants.
- The technique demonstrated reduced large ribosomal subunit assembly or function in affected individuals.
- This functional assay provides a method to interpret variants of unknown significance in DBA.
Implications:
- Optimized polysome profiling serves as a valuable adjunctive tool for validating large ribosomal protein variants in DBA.
- This method can aid in the diagnosis and understanding of DBA pathogenesis.
- Further validation is needed across diverse DBA mutations and patient subgroups.

